Home › Cancro colorettale › Virginia
Studi clinici su Cancro colorettale nello stato di Virginia
76 studi su Cancro colorettale cercano partecipanti presso sedi nello stato di Virginia.
Città nello stato di Virginia
- Arlington52 studi
- Richmond13 studi
- Charlottesville10 studi
- Roanoke10 studi
- Norfolk5 studi
- Winchester3 studi
- Alexandria3 studi
Testo ufficiale dello studio (inglese)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- Bon Secours Saint Mary's Hospital, Richmond
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05673148Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- University of Virginia Health, Charlottesville
In reclutamento
Età da 65 a 82 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05612347A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Blue Ridge Cancer Care - Blacksburg /ID# 280115, Blacksburg
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07525206The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- e altri 7
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Family Communications After Genetic Testing
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
In reclutamentoVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07143487Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #66, Charlottesville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06324357A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 2, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07085091A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- UVA Comprehensive Cancer Center, Charlottesville
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07659795A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Virginia Cancer Specialists - Fairfax /ID# 271351, Fairfax
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06820463Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Virginia Cancer Specialists, PC, Arlington
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg
- Virginia Cancer Specialists, PC, Fairfax
- e altri 12
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- NEXT Oncology, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05482893A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295), Roanoke
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06428409A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Virginia Cancer Specialists, Arlington
- Richmond VA Medical Center, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06750094A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Virginia Cancer Specialists, Arlington
- Inova Schar Cancer Institute Dept of Fairfax Hospital, Fairfax
- Richmond VA Medical Center, Richmond
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06662786A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Local Institution - 0278, Fairfax
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07221357Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06102902Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06445062A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
- NEXT Virginia, Faifax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07693751A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Next Oncology Virginia Cancer Specialist, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NEXT Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- University of Virginia Medical Center, Charlottesville
- Mary Washington Healthcare, Fredericksburg
- Hematology Oncology Associates of Fredericksburg Admin, Fredericksburg
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07284849A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Virginia Oncology Associates, Newport News
- Blue Ridge Cancer Care - 300202915, Roanoke
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07549412A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- NEXT Oncology, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06440005Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Charlottesville
- Clinical Study Site, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07228832The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- e altri 5
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età da 18 a 99 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT06983743A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Inova Schar Cancer, Fairfax
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT06992258A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07227168A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
- NEXT Oncology, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT07321106Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
- Virginia Cancer Institute (VCI), Richmond
- Virginia Commonwealth University, Richmond
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06728072FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Virginia, Charlottesville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 ago 2026 · NCT07066657A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- NEXT Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT07397338Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.